SCHEMBL652685

SCHEMBL652685

CCCC[CH]Oc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 3/20 0.47
MLNR O43193 1/20 0.39
NR1I2 O75469 1/20 0.39
ESR1 P03372 1/20 0.39
NR3C1 P04150 1/20 0.39
PGR P06401 1/20 0.39
ADRB2 P07550 1/20 0.39
CHRM2 P08172 1/20 0.39
ADRB1 P08588 1/20 0.39
HTR1A P08908 1/20 0.39
ADRA2A P08913 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
CHRM1 P11229 1/20 0.39
DRD2 P14416 1/20 0.39
ADRA2B P18089 1/20 0.39
ADRA2C P18825 1/20 0.39
CHRM3 P20309 1/20 0.39
MAOA P21397 1/20 0.39
CNR1 P21554 1/20 0.39
SLC6A2 P23975 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL650880 0.94 LTA4H (0.47) LTA4HMLNRNR1I2ESR1NR3C1
Aluminum Chloride Anhydrous SCHEMBL28757318 0.93 LTA4H (0.42) LTA4HMLNRNR1I2ESR1NR3C1
SCHEMBL10639345 0.92 LTA4H (0.46) LTA4HMLNRNR1I2ESR1NR3C1
SCHEMBL10420432 0.92 LTA4H (0.46) LTA4HMLNRNR1I2ESR1NR3C1
SCHEMBL10334473 0.92 LTA4H (0.46) LTA4HMLNRNR1I2ESR1NR3C1
SCHEMBL2941920 0.92 LTA4H (0.46) LTA4HMLNRNR1I2ESR1NR3C1
SCHEMBL1720912 0.92 LTA4H (0.46) LTA4HMLNRNR1I2ESR1NR3C1
SCHEMBL6036675 0.92 LTA4H (0.46) LTA4HMLNRNR1I2ESR1NR3C1
SCHEMBL27947956 0.92 LTA4H (0.46) LTA4HMLNRNR1I2ESR1NR3C1
SCHEMBL5073229 0.92 LTA4H (0.46) LTA4HMLNRNR1I2ESR1NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104224781-B The pyridine compounds and their and its new application of one group of 2- amide groups -3- alkoxy substitution 中国医学科学院医药生物技术研究所 2018-09-25 CN claimed
CN-101426805-A Method for detaching protecting group on nucleic acid NIPPON SHINYAKU CO LTD (JP) 2009-05-06 CN claimed
JP-4237257-B2 2009-03-11 JP claimed
US-20060205938-A1 Monohydrate solvates of loracarbef RANBAXY LABORATORIES LIMITED (IN) 2006-09-14 US claimed
EP-1565462-A1 MONOHYDRATE SOLVATES OF LORACARBEF RANBAXY LABORATORIES, LTD. (IN) 2005-08-24 EP claimed
WO-2004046142-A1 MONOHYDRATE SOLVATES OF LORACARBEF RANBAXY LABORATORIES LIMITED (IN) 2004-06-03 WO claimed
EP-1021388-B1 PHOSPHORYLATION PROCESS AND CATALYST BIONERIS AB (SE) 2003-06-25 EP claimed
US-6479656-B1 Phosphorylation process and catalyst PERSTORP AB (SE) 2002-11-12 US claimed
US-6468664-B1 CAN BE APPLIED TO A PASSIVATION LAYER WITHOUT AN ADHESIVE AGENT OR AN ADHESIVE TAPE FOR PACKAGING LOC(LEAD-ON-CHIP) AND WHICH HAS AN EXCELLENT PHOTORESIST WETABILITY AND AN EXCELLENT ADHESION WITH BOTH A SILICON CHIP AND A LEAD FRAME. SAMSUNG ELECTRONICS CO., LTD. (KR) 2002-10-22 US claimed
JP-2001501910-A 2001-02-13 JP claimed
EP-1021388-A1 PHOSPHORYLATION PROCESS AND CATALYST PERSTORP AB (SE) 2000-07-26 EP claimed
EP-0656008-B1 THROMBIN RECEPTOR ANTAGONISTS COR THERAPEUTICS INC (US) 2000-03-15 EP claimed
EP-0920414-A1 MATRIX METALLOPROTEINASE INHIBITORS PHARMACIA & UPJOHN S.p.A. (IT) 1999-06-09 EP claimed
US-5866681-A OLIGOPEPTIDES COR THERAPEUTICS, INC. (US) 1999-02-02 US claimed
WO-1997049674-A1 MATRIX METALLOPROTEINASE INHIBITORS PHARMACIA & UPJOHN S.P.A. (IT) 1997-12-31 WO claimed
JP-2675438-B2 1997-11-12 JP claimed
WO-1997034853-A1 PHOSPHORYLATION PROCESS AND CATALYST PERSTORP AB (SE) 1997-09-25 WO claimed
EP-0656008-A1 THROMBIN RECEPTOR ANTAGONISTS COR THERAPEUTICS, INC. (US) 1995-06-07 EP claimed
WO-1994003479-A1 THROMBIN RECEPTOR ANTAGONISTS COR THERAPEUTICS, INC. (US) 1994-02-17 WO claimed
WO-1993013089-A1 MACROCYCLIC POLYETHER CARBOXYLIC ACIDS URBAN FRANK J (US) 1993-07-08 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205938-A1 Monohydrate solvates of loracarbef SLC10A1, DCXR, KLK13 LTA4H 219/4885MLNR 136/4885NR1I2 1646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.